Drugs / unacylated ghrelin
unacylated ghrelin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03358355 | Jun 2016 → Aug 2017 | peripheral arterial disease | Northwestern University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01531283 | Feb 2011 → Apr 2013 | — | David Dalessio | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | unacylated ghrelin | “The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).” NCT03358355 ↗ |
| Known as | des-octanoyl ghrelin | “Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects.” NCT01531283 ↗ |
| Known as | UAG | “Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects.” NCT01531283 ↗ |
| Route | Intravenous | “IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)” NCT01531283 ↗ |